2-acetyl-phenanthrene-9,10-dione | 345631-40-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 2-acetyl-phenanthrene-9,10-dione
• 英文别名: 2-Acetyl-phenanthren-9,10-dion；2-Acetylphenanthrene-9,10-dione
• CAS: 345631-40-5
• 化学式: C₁₆H₁₀O₃
• 分子量: 250.254
• InChiKey: BMAYNALRCYVROT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  51.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-acetyl-phenanthrene-9,10-dione 在 selenium(IV) oxide 、 乙醇 、 溶剂黄146 作用下， 生成 2-quinoxalin-2-yl-dibenzo[a,c]phenazine
  参考文献：
  名称：

  Musante; Fatutta, Annali di Chimica, 1959, vol. 49, p. 1496,1515

  摘要：

  DOI：
• 作为产物：
  描述：

  菲 在 chromium(VI) oxide 、 三氯化铝 、 溶剂黄146 、 硝基苯 作用下， 生成 2-acetyl-phenanthrene-9,10-dione
  参考文献：
  名称：

  Semantic aspects of morphological processing: Transparency effects in Serbian

  摘要：

  We examined the contribution of semantics to morphological facilitation in the visual lexical decision task at two stimulus onset asynchronies (SOAs) with Serbian materials. Primes appeared in Roman or Cyrillic characters. Targets always were printed in Roman. When primes were presented at an SOA of 250 msec, decision latencies to verbal targets (e.g., VOLIM) showed greatest facilitation after inflectionally (e.g., VOLE) related primes, significantly less after semantically transparent derived primes (e.g., ZAVOLE), and less again after semantically opaque derived primes (e.g., PREVOLE). Latencies after semantically transparent and opaque derived target words did not differ at an SOA of 48 msec. Both were slower than after inflectionally related primes. Stated generally, effects of semantic transparency among derivationally related verb forms were evident at long SOAs, but not at short ones. Under alphabet-alternating conditions, magnitudes of facilitation were greater overall, but the pattern was similar. The outcome suggests that restricted processing time for the prime limits the contribution of semantics to morphological processing and calls into question accounts that posit a task-invariant semantic criterion for morphological decomposition within the lexicon.

  DOI：

  10.3758/bf03194964

文献信息

• Cd45 inhibitors
  申请人：——

  公开号：US20030207812A1

  公开（公告）日：2003-11-06

  Substituted phenanthrene-9,10-diones in accord with structural diagram I, 1 compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, R 1 at each occurrence is independently selected from hydrogen, halogen, NH-tosyl, N-di-tosyl, NH 2 , NO 2 , NH—CO—R 2 , CO—NH—R 2 , Ar, (CH 2 ) n CH(COOH)R 3 COR 3 and NHCOCH 2 CH(COOH)NHR 4 , where R 2 , R 3 and R 4 are a selected from a variety of substituted or unsubstituted alkyl and aryl groupstand oligopeptides.

  根据结构图I，以及其中的苯并蒽-9,10-二酮，其组成物和使用方法，用于治疗T细胞介导的情况，如自身免疫疾病和器官移植排斥。在本发明的化合物中，每个出现的R1独立地选自氢、卤素、NH-对甲苯磺酰基、N-二对甲苯磺酰基、NH2、NO2、NH-CO-R2、CO-NH-R2、Ar、(CH2)nCH(COOH)R3COR3和NHCOCH2CH(COOH)NHR4，其中R2、R3和R4选自各种取代或未取代的烷基和芳基以及寡肽。
• ＣＤ４５阻害剤
  申请人：——

  公开号：JP2003518085A

  公开（公告）日：2003-06-03

  \n (57)【要約】\n自己免疫異常及び臓器移植拒絶のようなＴ細胞が関与する容態の治療用の化学構造式（Ｉ）に合致する置換フェナントレン−９，１０−ジオン類、その組成物及びそれを利用する方法。本発明の化合物において、Ｒ1は各場合において水素、ハロゲン、ＮＨ−トシル、Ｎ−ジ−トシル、ＮＨ2，ＮＯ2，ＮＨ−ＣＯ−Ｒ2、ＣＯ−ＮＨ−Ｒ2、Ａｒ、（ＣＨ2）nＣＨ（ＣＯＯＨ）Ｒ3、ＣＯＲ3及びＮＨＣＯＣＨ2ＣＨ（ＣＯＯＨ）ＮＨＲ4から独立的に選択するが、ここにおけるＲ2、Ｒ3及びＲ4は置換又は非置換のアルキルとアリール基及びオリゴペプチドから選択する。\n【化１】\n\n

  \(57) [摘要]符合化学结构式(I)的取代菲-9,10-二酮用于治疗涉及T细胞的病症，如自身免疫异常和器官移植排斥反应，其组合物和使用方法相同。在本发明的化合物中，R1 在每种情况下都是氢、卤素、NH-对甲苯磺酸、N-二对甲苯磺酸、NH2、NO2、NH-CO-R2、CO-NH-R2、Ar、(CH2)nCH(COOH)R3、COR3 和 NHCOCH2CH(COOH)NHR4，其中 R2、R3 和 R4 分别独立地选自取代或未取代的烷基和芳基。选自寡肽。\Јn [Ј1] ЈnЈn
• THE PREPARATION OF 9,10-DIHYDROPHENANTHRENE AND ITS DERIVATIVES
  作者：Alfred Burger、Erich Mosettig

  DOI：10.1021/ja01315a512

  日期：1935.12
• CD45 INHIBITORS
  申请人：AstraZeneca AB

  公开号：EP1242363A2

  公开（公告）日：2002-09-25
• [EN] CD45 INHIBITORS<br/>[FR] INHIBITEURS DE CD45
  申请人：ASTRAZENECA AB

  公开号：WO2001046125A2

  公开（公告）日：2001-06-28

  Substituted phenantheren-9, 10-diones in accord with structural diagram (I), compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, R1 at each occurrence is independently selected from hydrogen, halogen, NH-tosyl, N-di-tosyl, NH¿2?, NO2, NH-CO-R?2¿, CO-NH-R2, Ar, (CH¿2?)nCH(COOH)R?3 COR3¿ and NHCOCH¿2?CH(COOH)NHR?4¿, where R?2, R3 and R4¿ are a selected from a variety of substituted or unsubstituted alkyl and aryl groups and oligopeptides.